Targeted cardiomyopathy drug, Camzyos effective in Asians
By Son, Hyung-Min | translator Kim, Jung-Ju
23.12.19 06:16:49
가나다라
0
Camzyos, a myosin inhibitor, emerges as the first targeted treatment for HCM
In a global clinical trial, Camzyos treatment brings half of patients to asymptomatic levels.
EXPLORER-CN, enrolling Chinese patients, results were consistent with those observed in global studies
▲Milind Y. Desai, a professor of Department of Cardiovascular Medicine at Cleveland Clinic, US
The first targeted treatment option for obstructive hypertrophic cardiomyopathy has finally emerged.Obstructive hypertrophic cardiomyopathy (oHCM) is a sub-classification of hypertrophic cardiomyopathy that is characterized by LV outflow tract (LVOT) obstruction impeding blood flow from the heart to the rest of the body.
Previously, the treatment options for HCM were limited to chronic disease treatments such as beta-blockers and calcium channel blockers. While these drugs could indirectly manage HCM symptoms, if there was no improvement, there were no other treatment options besides surgery.
In this context, BMS’s development of Camzyos offered a targeted therapy option
Son, Hyung-Min(shm@dailypharm.com)
If you want to see the full article, please JOIN US (click)